在整合型医疗系统中开展基于血液的结直肠癌筛查:患者依从性随机试验
在大型整合型医疗系统中,对既往未完成粪便免疫化学检测(FIT)且拟行临床就诊的45-75岁患者随机分组,比较提供商业化结直肠癌血液检测与常规照护的3个月筛查完成率。血液检测组筛查比例较常规照护组高17.5个百分点(30.5% vs 13.0%;OR 2.94,95% CI 2.34-3.70;p<0.001)。作者结论认为提供血液检测可提升筛查率,但需进一步研究如何平衡依从性与较其他可用检测更低的进展期腺瘤检出。
要点
- 对既往未完成FIT的45-75岁患者,提供血液检测使3个月筛查完成率提高17.5个百分点(30.5% vs 13.0%)。
- 血液检测组与常规照护组的筛查完成比值比为OR 2.94(95% CI 2.34-3.70;p<0.001)。
- 作者指出需进一步研究如何平衡良好依从性与较其他可用检测更低的进展期腺瘤检出。
核心结论
- 在既往拒绝结直肠癌筛查的成人中,提供基于血液的筛查检测使结直肠癌筛查率较常规照护提高17.5个百分点。
- 作者指出需进一步研究如何平衡良好依从性与较其他可用检测更低的进展期腺瘤检出。
研究设计与样本
- 研究为随机对照试验,在大型整合型医疗系统中将45-75岁、既往3-9个月内被提供但未完成FIT且已安排临床就诊的患者按1:1随机分配至提供商业化结直肠癌血液检测(Shield,Guardant Health)组或常规照护组。
- 共随机2026例患者,随机后排除后2004例仍符合条件(常规照护组1003例,血液检测组1001例;平均年龄60岁,女性62%,非西班牙裔白人80%)。
- 血液检测组1001例中,经病历审查排除后招募924例;其中548例(59.3%)通过电话联系到,280例(51.1%)预约了研究团队的面诊。
- 主要比较两组3个月结直肠癌筛查比例。
- 试验注册号:NCT05987709。
主要发现
- 血液检测组3个月结直肠癌筛查比例为30.5%,常规照护组为13.0%,血液检测组较常规照护组高17.5个百分点(OR 2.94,95% CI 2.34-3.70;p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需进一步研究如何平衡良好依从性与较其他可用检测更低的进展期腺瘤检出。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option if offered one during health encounters. Blood-based screening tests for CRC could add to the total number of people screened for CRC by providing another testing alternative. DESIGN: Study participants were patients aged 45-75 years at a large, integrated health system who were offered but did not complete an FIT in the prior 3-9 months and were scheduled for a clinical encounter. Individuals were randomised (1:1) to be offered a commercially available CRC blood test (Shield, Guardant Health) versus usual care. We compared 3-month CRC screening proportions in the two groups. RESULTS: We randomised 2026 patients; 2004 remained eligible following postrandomisation exclusions (1003 to usual care and 1001 to blood draw offer; mean age: 60, 62% female, 80% non-Hispanic white). Of the 1001 allocated to the blood test group, 924 were recruited following chart-review exclusions; 548 (59.3%) were reached via phone, of which 280 (51.1%) scheduled an appointment with the research team. CRC screening proportions were 17.5 percentage points higher in the blood test group versus usual care (30.5% vs 13.0%; OR 2.94, 95% CI 2.34 to 3.70; p<0.001). CONCLUSION: Among adults who had declined prior CRC screening, the offer of a blood-based screening test boosted CRC screening by 17.5 percentage points over usual care. Further research is needed on how to balance the favourable adherence with lower advanced adenoma detection compared with other available tests. TRIAL REGISTRATION NUMBER: NCT05987709.
引用
- Coronado GD, Jenkins CL, Shuster E, et al. Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence. Gut. 2024. PMID: 38176899. doi:10.1136/gutjnl-2023-330980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。